|
Median progression free survival (PFS) for patients treated with everolimus (EVE) + exemestane (EXE) for HR+ mBC in routine clinical practice: Results of the 3rd interim analysis of the non-interventional trial BRAWO. |
|
|
|
Travel, Accommodations, Expenses - Novartis |
|
|
Honoraria - Amgen; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Novartis; Pfizer; Roche |
Research Funding - Amgen; Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Novartis; Roche |
Consulting or Advisory Role - Novartis; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Pfizer; Pierre Fabre; Roche; Sividon Diagnostics |
Consulting or Advisory Role - Celgene; Pfizer; Pierre Fabre; Roche; Sividon Diagnostics |
Research Funding - Pierre Fabre |
Patents, Royalties, Other Intellectual Property - patents pending; Sividon Diagnostics |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Celgene |
|
|
|
Consulting or Advisory Role - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
|
|
|
|
|
No Relationships to Disclose |